Clinical Trials
73 trialsNCT02567435 2026-05-27
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00980460 2026-05-04
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00977574 2026-04-29
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01946529 2026-02-23
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT01210482 2024-09-25
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Pfizer
Completed
NCT00700258 2024-09-23
STAR-TOR
Pfizer
Completed
NCT01517243 2023-09-21
Phase II Study of Alternating Sunitinib and Temsirolimus
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT01614197 2023-07-27
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT01767194 2022-10-24
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00112840 2022-02-01
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01381692 2021-10-04
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01051557 2021-07-19
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01827943 2021-05-06
VESTOR
Institut Bergonié
Phase 2 Completed
NCT01687673 2020-12-07
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
Phase 2 Completed
NCT01369433 2020-09-01
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
AVEO Pharmaceuticals, Inc.
Phase NA Terminated
NCT00376688 2020-02-24
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01281917 2019-12-13
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
University of Wisconsin, Madison
Phase 2 Completed
NCT01076543 2019-10-16
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01083368 2019-08-21
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT01196429 2019-08-08
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00429793 2019-07-24
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00723255 2019-07-23
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00729586 2019-07-23
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01016769 2019-06-26
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01026623 2019-06-17
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01180049 2019-05-20
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Pfizer
Phase 4 Completed
NCT00949325 2019-03-11
Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT01010126 2019-01-25
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01614795 2018-12-11
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00378703 2018-11-14
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00329719 2018-10-16
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01111825 2018-09-26
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
NCT00838539 2018-09-18
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
Puma Biotechnology, Inc.
Phase 1 Completed
NCT01025453 2018-08-15
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01378377 2018-07-30
Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus
EMD Serono
Phase 1 Terminated
NCT01827267 2018-07-03
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00335764 2018-07-02
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00699491 2018-06-13
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00782275 2018-01-24
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01646021 2018-01-19
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT00775593 2017-11-09
AML1107
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00397982 2017-06-09
Mel47
National Cancer Institute (NCI)
Phase 2 Completed
NCT00808899 2017-05-30
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01222715 2017-05-05
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01256385 2017-03-27
MAESTRO HN
National Cancer Institute (NCI)
Phase 2 Completed
NCT00093782 2017-02-07
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00921310 2016-12-13
Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
Washington University School of Medicine
Phase 1/2 Terminated
NCT01061606 2016-11-09
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
National Cancer Institute (NCI)
Phase 2 Terminated